Eloxx Pharmaceuticals, Inc.
ELOXNasdaqCIK 1035354HealthcareFiscal year ends Dec 31
Reports and events: 374 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2223:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001193125-26-428116 |
| 2026-09-1121:28 ET | S-1 | Registration statement | 0001193125-26-389422 |
| 2026-08-1121:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345032 |
| 2026-08-1121:02 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344964 |
| 2026-06-0421:17 ET | S-1/A | Registration statement, amended | 0001193125-26-257750 |
| 2026-06-0120:55 ET | S-1/A | Registration statement, amended | 0001193125-26-251655 |
| 2026-06-0111:00 ET | 8-K | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-249692 |
| 2026-05-0720:57 ET | S-1 | Registration statement | 0001193125-26-212324 |
| 2026-05-0501:04 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-204722 |
| 2026-05-0120:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-201408 |
| 2026-03-1721:44 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-108687 |
| 2025-08-1221:22 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-25-076933 |
| 2024-10-1720:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-24-109521 |
| 2024-08-2000:13 ET | SC 13D/A | Ownership report, active investor, amended | 0001062993-24-015470 |
| 2024-07-1621:23 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-24-080251 |
| 2024-03-2920:11 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-24-041148 |
| 2024-03-1420:30 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-24-034529 |
| 2024-01-0922:10 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001104659-24-002631 |
| 2023-12-2821:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-23-130052 |
| 2023-12-1521:10 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-23-126400 |
| 2023-11-1321:58 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-117308 |
| 2023-11-1321:10 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062940 |
| 2023-10-1621:26 ET | 8-K | 3.01 Delisting notice | 0001104659-23-109423 |
| 2023-09-2020:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-23-102293 |
| 2023-09-1812:05 ET | 8-K | 8.01 Other events | 0001104659-23-101394 |
| 2023-09-1521:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-23-101272 |
| 2023-09-0714:14 ET | 8-K | 8.01 Other events | 0001104659-23-098843 |
| 2023-08-2920:32 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-23-096572 |
| 2023-08-2120:50 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-23-093964 |
| 2023-08-1415:56 ET | 8-K | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001104659-23-091130 |
| 2023-08-1120:05 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-041837 |
| 2023-08-0320:01 ET | 8-K | 8.01 Other events | 0001104659-23-087248 |
| 2023-07-1312:43 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-080576 |
| 2023-06-2322:32 ET | 8-K | 5.07 Shareholder vote results | 0001104659-23-073875 |
| 2023-06-1513:15 ET | 8-K | 8.01 Other events | 0001104659-23-071430 |
| 2023-06-0700:32 ET | 8-K | 8.01 Other events | 0001104659-23-068637 |
| 2023-05-2412:07 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-063884 |
| 2023-05-1622:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-060978 |
| 2023-05-1220:41 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-021821 |
| 2023-04-2820:03 ET | DEF 14A | Proxy statementPeriod 2023-06-22 | 0001140361-23-021490 |
| 2023-04-1420:06 ET | 8-K | 3.01 Delisting notice | 0001104659-23-045573 |
| 2023-04-0313:27 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-040585 |
| 2023-03-3120:02 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-011360 |
| 2023-03-0921:12 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000950170-23-007032 |
| 2022-12-0122:04 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-123704 |
| 2022-11-1421:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-118535 |
| 2022-11-1021:18 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-024490 |
| 2022-10-3120:31 ET | DEF 14A | Proxy statementPeriod 2022-11-30 | 0001140361-22-039123 |
| 2022-10-1420:31 ET | 8-K | 3.01 Delisting notice | 0001104659-22-108877 |
| 2022-09-1512:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-100245 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.